Peter Rankin

Vice President

Dr. Peter J. Rankin, Vice President, has been a member of CRA’s Life Sciences Practice since 1999, specializing in economic and strategic evaluation.

His pharmaceutical research includes assessment of patent extension antitrust claims, class certification analysis, monetary damages from commercial and intellectual property disputes, international arbitration involving contract disputes, abbreviated new drug applications (ANDAs), and product reimbursement strategies. In addition, Dr. Rankin has authored public and proprietary policy evaluation projects involving healthcare reform, reimbursement methodologies, antitrust exemptions, research and development incentives, and research productivity. Dr. Rankin has served as an expert in litigation and arbitration, and has testified before Congress.

While a doctoral candidate at Duke University, Dr. Rankin was a researcher at the Center for Health Policy, Law, and Management, where he published papers on hospital conversions; medical malpractice; and managed care quality, satisfaction, and participation. His dissertation research evaluated pricing and product differentiation in the Medicare-managed care market.

Selected Engagements

  • 01
    AAA arbitration regarding a collaboration and license agreement
    CRA provided expert reports and testimony on behalf of the respondent in an AAA arbitration concerning a collaboration and license agreement.  It was alleged...
    View engagement
  • 02
    AAA arbitration regarding breach of purchase agreement
    CRA was retained by the claimant in a dispute at AAA alleging breach of a purchase agreement due to the respondent’s alleged failure to make contracted minimum...
    View engagement
  • 03
    AAA arbitration regarding medical device licensing agreement
    In AAA arbitration, CRA was retained by respondent regarding the interpretation of commercial terms in a licensing agreement related to medical devices.  CRA...
    View engagement